Latest stories on VNRX
VolitionRx presents early stage I solid cancer detection at ESMO MAP Conference
The Fly56 · neutralproduct/pr
Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference
PR Newswire63 · neutralproduct/pr
VOLITIONRX LTD (VNRX) files 8-K
SEC 8-K50 · neutralgeneral
VolitionRx Issues Shares to Convert Senior Debt
TipRanks24 · bearishgeneral
VOLITIONRX LTD (VNRX) files 8-K
SEC 8-K34 · bearishgeneral
VolitionRx files to sell 10.01M shares of common stock for holders
The Fly24 · bearishgeneral
VolitionRx Accelerates Commercial Momentum with 112% Revenue Growth and Breakthroughs in Multi-Billion Dollar Diagnostics Markets
MarketChameleon73 · bullishproduct/pr
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
PR Newswire67 · bullishproduct/pr
VolitionRx announces publication on Nu.Q NETs H3.1 biomarker
The Fly56 · neutralproduct/pr
Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis
PR Newswire67 · bullishproduct/pr
VOLITIONRX LTD (VNRX) files 8-K
SEC 8-K34 · bearishgeneral
Volition (VNRX) Q2 2026 Earnings Call Transcript
Yahoo Finance56 · neutralearnings
Volition (VNRX) Q2 2026 Earnings Call Transcript
The Motley Fool56 · neutralearnings
Benchmark reiterates Hold on VolitionRX stock amid cost cuts
Investing.com Analyst Ratings50 · neutralanalyst
VolitionRx outlines September DETECSEPS start while targeting $5M feline milestone publication
Seeking Alpha56 · neutralproduct/pr
VolitionRx Limited (VNRX) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
VOLITIONRX LTD (VNRX) files 8-K
SEC 8-K50 · neutralgeneral
VolitionRX reports Q2 results
Seeking Alpha50 · neutralearnings
VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update
PR Newswire50 · neutralgeneral
Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients
PR Newswire63 · neutralproduct/pr
VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update
PR Newswire50 · neutralgeneral
VolitionRx Issues Shares to Settle Convertible Note Obligations
TipRanks24 · bearishgeneral
VOLITIONRX LTD (VNRX) files 8-K
SEC 8-K34 · bearishgeneral
Volition Reveals Peer-Reviewed Breakthrough: Capture-Seq Boasts Over 99% Pure Tumor DNA for Early Cancer Detection
August 5, 2026
MarketChameleon73 · bullishproduct/pr
Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology
PR Newswire63 · neutralproduct/pr